AbbVie Inc. (ABBV)


NYSE - NYSE Real Time Price. Currency in USD
62.82-1.40 (-2.18%)
At close: 4:01 PM EDT

62.82 0.00 (0.00%)
After hours: 4:39 PM EDT

People also watch:
ABTGILDCELGBMYBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open64.30
Prev Close64.22
Bid62.84 x 200
Ask63.15 x 900
Day's Range62.80 - 64.31
52wk Range45.45 - 68.12
1y Target EstN/A
Market Cap104.54B
P/E Ratio (ttm)18.12
Beta1.42
Volume6,064,672
Avg Vol (3m)6,951,065
Dividend & Yield2.28 (3.53%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire19 hours ago

    AbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline

    SINGAPORE, Sept. 28, 2016 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, today strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site. This facility supports the growth of AbbVie's oncology and women's health pipeline and reflects progress from AbbVie's two previous announcements for manufacturing investment in Asia in 2014. The new 120,000 square-meter site – located in the Tuas Biomedical Park – is AbbVie's first manufacturing facility in Asia and will also include a biologics manufacturing facility that is expected to be fully operational by the end of 2018.

  • PR Newswire19 hours ago

    AbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline

    SINGAPORE, Sept. 29, 2016 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, today strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site. This facility supports the growth of AbbVie's oncology and women's health pipeline and reflects progress from AbbVie's two previous announcements for manufacturing investment in Asia in 2014.

  • Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
    Zacks23 hours ago

    Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo

    Bristol-Myers Squibb (BMY) inked a clinical collaboration agreement with Nektar Therapeutics to evaluate Opdivo-NKTR-214 combination in phase I/II studies.